The tenth International Symposium on Minimal Residual Cancer (ISMRC) will be held in Hamburg from March 19-21, 2016. Over 300 delegates from 28 countries are expected to attend the event in the University Medical Center Hamburg-Eppendorf (HKE) where the focus will be on LIQUID BIOPSY. This has been developed by a group of researchers led by Prof. Dr. Klaus Pantel, Director of the Insitute for Tumour Biology at UKE.
Pantel, who will direct the symposium, said: “We wish to develop blood tests that allow us to identify characteristics of different types of cancer for therapy purposes.” The objective is use the bloodtests to pave the way towards cancer therapy suited to individual patients in terms of LIQUID BIOPSY.
European “Cancer ID” project
The concept of LIQUID BIOPSY has formed the basis of the European cancer research project since April 2015. A total of 33 institutions and companies from 13 countries have formed a research network as part of the EU’s Innovative Medicines Initiative (IMI). The “CANCER ID” project will run for five years. It has received EUR 6.6 million in EU funds. Partners in industry will pay another EUR 8.2 million towards research.
ISMRC has been held since 1996 and was last held in Paris in 2013. The 2016 meeting in Hamburg is organized together with the newly established EU IMI consortium CANCER-ID and brings together basic and clinical researchers from academia and companies.